Skip to Content
Søk Menu

EADV24: Semaglutide Shows Promising Outcomes for Obese Patients with Hidradenitis Suppurativa

A study presented Wednesday, 25 September 2024, at the EADV Congress 2024 in Amsterdam highlights the significant potential of semaglutide in treating hidradenitis suppurativa (HS) in obese patients.

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Relatert innhold

LBA: Lebrikizumab Provides Long-Term Efficacy and Safety in Atopic Dermatitis with a Well-Tolerated Safety Profile

/ Jan Andreasen
Atopisk dermatittEADV24
Teo Helkkula

No Significant Changes in Incidence or Survival Rates of Acral Melanoma in Sweden

/ Teo Helkkula
EADV24 Play the Video 04:45
Anna Sophie Nicolo Belling Krontoft

Conversation Cards for Patients with Atopic Dermatitis

/ Anna Sophie Belling Krontoft
Atopisk dermatittEADV24 Play the Video 2:56
April Armstrong

Exciting Data on Atopic Dermatitis from EADV 2024

/ April Armstrong
Atopisk dermatittEADV24 Play the Video 04:14
Melinda J Gooderham

Key Findings on Deucravacitinib – A New Oral Treatment for Psoriasis

/ Melinda J. Gooderham
EADV24Psoriasis Play the Video 02:51

EADV24: New Insights Into Chronic Wound Healing – A Significant Step Forward to Changed Clinical Practice

/ Jan Andreasen
EADV24Sårtilheling
Claus Otto Carl Zachariae

EADV 2024: Promising News in Hand Eczema Treatment

/ Claus Otto Carl Zachariae
EADV24Eksem Play the Video 01:52
Marcela Nowak

A Multidisciplinary Approach to Chronic Leg Ulcers is Important so that Rarer Causes Go Undiagnosed

/ Marcela Nowak
EADV24 Play the Video 7:09

EADV24: New Research Confirms Link Between Stress and Psoriasis Relapse

/ Sofie Pohl
EADV24Psoriasis
Back to top